Anti-VEGF durability real-world vs trial gap

Peer-reviewed real-world data on long-acting anti-VEGF agents is now mature enough to characterise the gap between trial-reported maxima and real-world treat-and-extend dosing intervals. The commercial value of the agents that close that gap most cleanly is materially above the rest.